Clinical trial
The Efficacy and Safety of Risperidone in the Treatment of Adolescents With…
NCT00034749 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00034749 |
|---|---|
| Title | The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia |
| Official title | The Efficacy and Safety of Risperidone in Adolescents With Schizophrenia: a Comparison of Two Dose Ranges of Risperidone |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Risperidone |
| Enrollment | 279 |
| Start date | Apr 1, 2001 |
| Completion | Mar 1, 2006 |
| First posted | May 3, 2002 |
| Last update posted | Jun 8, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: